Xeris Pharmaceuticals Inc. (XERS) Misses Q4 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Xeris Biopharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Events
March 10, 2022 7:00 AM ESTAcquisition and integration of Strongbridge Biopharma completed; $50M in synergies to be realized by year-end 2022
Recorlev® approved by FDA
FY 21 pro forma net product revenues of $79M a 56% increase from prior year
Well-capitalized with cash, cash equivalents, and short-term investments of $102.4M at YE 2021
Double-digit net product revenues growth expected in 2022 to be $105M - $120M
Cash position further strengthened with a recent PIPE and the restructuring of debt with Hayfin Capital; 2022 year-end cash, cash equivalents,... More
